← Back to Search

Other

Combination - CITI-002 (low dose) for Hemorrhoids

Phase 2
Waitlist Available
Led By Alan Lader, PhD
Research Sponsored by Citius Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 8
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a special cream called CITI-002 for adults with moderate to severe hemorrhoids. The cream is applied regularly for a short period. Researchers want to see if it helps reduce pain and swelling. They will check patients' progress through surveys and regular visits.

Eligible Conditions
  • Hemorrhoids

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 8 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Hemorrhoid symptoms
Secondary study objectives
Change in Hemorrhoidal bother.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Group I: Combination-CITI-002 (low dose) creamExperimental Treatment1 Intervention
Topical cream applied to the peri-anal area twice daily for seven days.
Group II: Combination-CITI-002 (high dose) creamExperimental Treatment1 Intervention
Topical cream applied to the peri-anal area twice daily for seven days.
Group III: Monad 1 creamActive Control1 Intervention
Topical cream applied to the peri-anal area twice daily for seven days.
Group IV: Monad 2 creamActive Control1 Intervention
Topical cream applied to the peri-anal area twice daily for seven days.
Group V: Monad 3 creamActive Control1 Intervention
Topical cream applied to the peri-anal area twice daily for seven days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Combination - CITI-002 (low dose)
2022
Completed Phase 2
~310
Combination - CITI-002 (high dose)
2022
Completed Phase 2
~310

Find a Location

Who is running the clinical trial?

Citius Pharmaceuticals, Inc.Lead Sponsor
1 Previous Clinical Trials
211 Total Patients Enrolled
1 Trials studying Hemorrhoids
211 Patients Enrolled for Hemorrhoids
Therapeutics, Inc.Industry Sponsor
30 Previous Clinical Trials
3,608 Total Patients Enrolled
Alan Lader, PhDPrincipal InvestigatorCitius Pharmaceuticals
~87 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top